Morgan Stanley
NAUT icon

Morgan Stanley’s Nautilus Biotechnolgy NAUT Stock Holding History

Morgan Stanley’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
98,212
+48,709
+98% +$129K ﹤0.01% 5985
2026
Q1 		$192K Buy
49,503
+10,919
+28% +$26.8K ﹤0.01% 5892
2025
Q4 		$75.2K Buy
38,584
+12,856
+50% +$21.1K ﹤0.01% 6294
2025
Q3 		$21.7K Sell
25,728
-28,849
-53% -$21.2K ﹤0.01% 6666
2025
Q2 		$39.6K Sell
54,577
-117,584
-68% -$88.3K ﹤0.01% 6432
2025
Q1 		$148K Sell
172,161
-221,445
-56% -$329K ﹤0.01% 5850
2024
Q4 		$661K Sell
393,606
-6,882
-2% -$16.5K ﹤0.01% 5302
2024
Q3 		$1.14M Buy
400,488
+78,928
+25% +$204K ﹤0.01% 4978
2024
Q2 		$752K Sell
321,560
-85,031
-21% -$222K ﹤0.01% 5121
2024
Q1 		$1.2M Sell
406,591
-34,175
-8% -$97K ﹤0.01% 4868
2023
Q4 		$1.32M Buy
440,766
+37,956
+9% +$109K ﹤0.01% 4773
2023
Q3 		$1.27M Sell
402,810
-19,268
-5% -$62.7K ﹤0.01% 4652
2023
Q2 		$1.63M Buy
422,078
+7,896
+2% +$22.7K ﹤0.01% 4547
2023
Q1 		$1.15M Buy
414,182
+42,568
+11% +$89.3K ﹤0.01% 4780
2022
Q4 		$669K Buy
371,614
+75,359
+25% +$145K ﹤0.01% 5084
2022
Q3 		$629K Buy
296,255
+178,193
+151% +$448K ﹤0.01% 5146
2022
Q2 		$318K Buy
118,062
+66,967
+131% +$249K ﹤0.01% 5650
2022
Q1 		$222K Buy
51,095
+8,664
+20% +$35.6K ﹤0.01% 5862
2021
Q4 		$221K Buy
42,431
+11,675
+38% +$62.5K ﹤0.01% 6016
2021
Q3 		$189K Buy
30,756
+30,256
+6,051% +$241K ﹤0.01% 6034
2021
Q2 		$5K Sell
500
-1,343
-73% -$14.5K ﹤0.01% 7383
2021
Q1 		$25K Sell
1,843
-3,411
-65% -$47.3K ﹤0.01% 6645
2020
Q4 		$57K Buy
5,254
+3,667
+231% +$38.6K ﹤0.01% 6117
2020
Q3 		$17K Buy
+1,587
New +$16.9K ﹤0.01% 6117

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Morgan Stanley's NAUT Position: Q2 2026 in Review

Morgan Stanley increased its Nautilus Biotechnolgy (NAUT) stake by 98% in Q2 2026, buying an estimated $129K and bringing the position to 98,212 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #5985.

Morgan Stanley first reported a position in NAUT in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.63M in Q2 2023. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Morgan Stanley held 98,212 shares of Nautilus Biotechnolgy worth $184K as of Q2 2026.
  • Morgan Stanley bought 48,709 Nautilus Biotechnolgy shares in Q2 2026, an estimated $129K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5985 holding.
  • Morgan Stanley first reported a position in Nautilus Biotechnolgy in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Nautilus Biotechnolgy position peaked at $1.63M in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.